Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy?. (28th May 2023)

• Record Type: Journal Article
• Authors: Ghorbaninezhad, Farid; Alemohammad, Hajar; Najafzadeh, Basira; Masoumi, Javad; Shadbad, Mahdi Abdoli; Shahpouri, Mohammad; Saeedi, Hossein; Rahbarfarzam, Omid; Baradaran, Behzad
• Is Part Of: Cancer letters. Volume 562(2023)
• Publication Date: 2023-05-28
• Subjects: Dendritic cells -- Dexosomes -- CD4+ T cells -- CD8+ T cells -- NK cells -- Cancer immunotherapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2023.216168
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Dendritic cells (DCs) release nanometer-sized membrane vesicles known as dexosomes, containing different molecules, particularly proteins, for presenting antigens, i.e., major histocompatibility complex (MHC)-I/II and CD86. Dexosomes can, directly and indirectly, stimulate antigen-reactive CD8 + and CD4 + T cell responses. Antigen-loaded dexosomes can lead to the development of potent anti-tumoral immune responses. Notably, developing dexosome-based cell-free vaccines could serve as a new vaccination platform in the era of immunotherapy for various cancers. Furthermore, combining dexosomes vaccination strategies with other treatment approaches can considerably increase tumor-specific T cell responses. Herein, we aimed to review how dexosomes interact with immune cells, e.g., CD4 + and CD8 + T cells and natural killer (NK) cells. Besides, we discussed the limitations of this approach and suggested potential strategies to improve its effectiveness for affected patients. Highlights: DC-secreted exosomes called dexosomes, playing a role in cancer immunotherapy. Dexosome-based therapies were beneficial in (pre)clinical investigations. Presence of MHC-I/II and costimulatory molecules on dexosomes stimulate immune cells.